LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.34 0.75

Buy Sell

Overview

Share price change

24h

Current

Min

1.27

Max

1.3599999999999999

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+69.17% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.2M 173M
Previous open	0.59
Previous close	1.34

News Sentiment

By Acuity

20%

80%

22 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 mar 2026, 18:13 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mar 2026, 17:20 UTC

Major News Events

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mar 2026, 17:15 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mar 2026, 00:00 UTC

Major News Events

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mar 2026, 23:52 UTC

Market Talk

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mar 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 23:46 UTC

Market Talk

Major News Events

Correction to Crude Prices Market Talk on March 9

9 mar 2026, 23:42 UTC

Market Talk

Major News Events

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mar 2026, 23:08 UTC

Major News Events

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mar 2026, 23:07 UTC

Major News Events

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mar 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mar 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 mar 2026, 20:47 UTC

Major News Events

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mar 2026, 20:33 UTC

Major News Events

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mar 2026, 20:14 UTC

Market Talk

Major News Events

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mar 2026, 19:33 UTC

Major News Events

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mar 2026, 19:17 UTC

Market Talk

Major News Events

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mar 2026, 19:14 UTC

Market Talk

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mar 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mar 2026, 18:23 UTC

Market Talk

Major News Events

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mar 2026, 17:58 UTC

Acquisitions, Mergers, Takeovers

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mar 2026, 17:57 UTC

Acquisitions, Mergers, Takeovers

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mar 2026, 17:41 UTC

Major News Events

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mar 2026, 17:41 UTC

Market Talk

Major News Events

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mar 2026, 17:08 UTC

Market Talk

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

9 mar 2026, 17:04 UTC

Market Talk

Major News Events

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

69.17% upside

12 Months Forecast

Average 2.25 USD 69.17%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

22 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.